1 Introduction. Trine Høyer Rose 1,2 Daniel Röshammar. Johnny T. Ottesen 2
|
|
- Brett O’Brien’
- 5 years ago
- Views:
Transcription
1 Drugs R D (2016) 16: DOI /s z ORIGINAL RESEARCH ARTICLE Characterisation of Population Pharmacokinetics and Endogenous Follicle-Stimulating Hormone (FSH) Levels After Multiple Dosing of a Recombinant Human FSH (FE ) in Healthy Women Trine Høyer Rose 1,2 Daniel Röshammar 1 Lars Erichsen 1 Lars Grundemar 1 Johnny T. Ottesen 2 Published online: 30 April 2016 The Author(s) This article is published with open access at Springerlink.com Abstract Objective The aim of this study was to characterise the population pharmacokinetics of FE , a novel recombinant human follicle-stimulating hormone (FSH), after multiple dosing in healthy women, taking into account endogenous FSH levels and the reproductive hormone dynamics. Methods Longitudinal measurements of FSH, luteinising hormone, progesterone, estradiol, and inhibin B levels were collected after repeated subcutaneous dosing with 225 IU of FE in 24 gonadotropin downregulated healthy women. The FSH data were described using nonlinear mixed-effects modelling. Results The measured FSH levels were modelled as a sum of endogenous FSH and FE The FE population pharmacokinetics were best described using a one-compartment model with first-order absorption and elimination, and a transit model for delayed absorption. The apparent clearance and volume of distribution increased with body weight in accordance with an allometrically scaled power exponent of 0.75 and 1, respectively. Endogenous FSH levels were lower in individuals with higher progesterone levels at baseline and were further suppressed over time with increasing inhibin B levels. Conclusions This characterisation of FE population pharmacokinetics after repeated dosing is in line with previous findings after single-dose administration. The results provide a basis for study design and data evaluation in the future development of recombinant FSH products, and show it can be of importance to account for endogenous FSH levels and its variation over time for accurate estimation of exogenously administered FSH pharmacokinetic parameters. Thus, correcting FSH concentrations by the observed endogenous FSH baseline value at all time points may be incorrect. Key Points The multiple-dose pharmacokinetics of FE have been described, accounting for endogenous follicle-stimulating hormone (FSH) levels. Exposure to FE was influenced by body weight, which may be a potential factor for individualised dosing recommendations. Endogenous FSH levels were influenced by progesterone and inhibin B levels. This time-varying contribution of endogenous FSH may be important to consider when characterising the pharmacokinetics of recombinant FSH products. & Trine Høyer Rose trinehrose@gmail.com 1 2 Experimental Medicine, Ferring Pharmaceuticals A/S, Kay Fiskers Plads 11, 2300 Copenhagen S, Denmark Department of Science, Systems and Models, Roskilde University, 4000 Roskilde, Denmark 1 Introduction Follicle-stimulating hormone (FSH) is a gonadotropin that is synthesised and secreted by the anterior pituitary gland. The major function of FSH is to regulate the reproductive processes by stimulating the gonads. In females, FSH
2 166 T. H. Rose et al. stimulates follicular development in the ovaries and production of inhibin B, progesterone, and oestrogens by the ovarian follicular granulosa cells. Luteinising hormone (LH), another gonadotropin from the anterior pituitary, stimulates the theca cells of the follicles to deliver androgens to the granulosa cells for conversion to oestrogens. It is also responsible for ovulation of the dominant follicle that has reached a fully mature, pre-ovulatory stage. The ovarian hormones promote further follicular development as well as exerting negative and positive feedback loops to the hypothalamus and pituitary affecting the gonadotropin production and secretion. In addition, gonadotropin secretion is stimulated by gonadotropin-releasing hormone (GnRH) produced in the hypothalamus. Female infertility can be caused by numerous factors at any level, from the hypothalamus to the ovaries and uterus. Gonadotropin therapy with either menotropins or recombinant FSH (rfsh) preparations can be used for infertility treatment when the cause is not primary ovarian failure, such that the ovaries are still responsive and contain primordial follicles. The purpose of controlled ovarian stimulation with daily administration of gonadotropins prior to assisted reproductive technologies such as in vitro fertilisation (IVF) or intracytoplasmic sperm injection (ICSI) is to obtain an adequate number of oocytes per retrieval, with minimum risks for the patient [1]. An appropriate ovarian response leading to the availability of several embryos makes it possible to select the best one(s) for transfer. Recently, a novel recombinant human FSH (rhfsh; FE , Ferring Pharmaceuticals A/S) was expressed for the first time in a human cell line (PER.C6 ; Crucell, Leiden, The Netherlands), while existing rfsh preparations in clinical use (e.g. follitropin-a and follitropinb) are derived from Chinese hamster ovary cell lines (CHO). Previously, in a population pharmacokinetic analysis of first-in-human data after single ascending doses [2], body weight was identified as a factor that negatively correlates with serum FE concentration. In the present work, the FE population pharmacokinetics were characterised after multiple dosing. The influence of body weight on drug exposure was investigated in order to further explore its importance as a factor for individualised FE dosing. Moreover, endogenous FSH levels may vary over time across the target patient group of infertile women, which may be an important aspect to consider in rfsh drug development and when analysing hormone data. The endogenous FSH contribution to the total FSH levels, and the influence of other reproductive hormones on the endogenous FSH levels, were therefore also evaluated in this analysis. 2 Methods 2.1 Clinical Trial Design and Data Data were generated in a randomised, double-blind, active control, multiple-dose trial with the aim of investigating the safety, tolerability, immunogenicity, pharmacokinetics, and pharmacodynamics of FE in healthy women. The trial was performed according to the Helsinki declaration and good clinical practice, and was approved by regulatory authorities and local Ethics Committees. All subjects gave written informed consent to participate. The trial has been described in more detail in a recent publication comparing the pharmacokinetic and pharmacodynamic properties of FE and GONAL-F (follitropin-a; EMD Serono, Inc., Rockland, USA) using non-compartmental analysis (NCA) [3]. Briefly, 49 healthy women were administered daily subcutaneous doses of 225 IU rfsh for 7 days; 24 of the 49 women were treated with FE and 25 women received GONAL-F as an active comparator. Prior to the trial (day -28 and -14), subjects were administered two doses of a GnRH agonist (LUPRON DEPOT, 1-month depot) to downregulate endogenous FSH. Blood samples for FSH, inhibin B, estradiol, progesterone, and LH measurements were collected at 60 and 30 min prior to administration of FE , immediately before administration, and once daily for 15 days. In addition, after administration of the last dose on day 6 and until day 8, the FSH concentration was measured every 4 h. Analysis of serum FSH concentrations was performed at Ferring Pharmaceuticals A/S using a validated immunoassay based on electrochemiluminescence (MSD sector TM Imager 2400) with a lower limit of quantification (LLOQ) of lg/l. The present analysis included data from the 24 women receiving FE Three of the 672 FSH measurements (0.4 %) were below the quantification limit and were excluded from further analysis. The personal demographics and baseline characteristics for the included subjects are listed in Table 1. Subjects with missing hormone baseline values were given the median population baseline value. Between days 6 and 8, FSH was measured every 4 h, and the other hormones were measured only once daily, leaving missing hormone values in between. To fill out the extra time points, the last measured hormone values were carried forward. 2.2 Pharmacokinetic Modelling The pharmacokinetic model was developed using nonlinear mixed-effects modelling, where both the population parameters, interindividual variability (IIV), and residual
3 Population PK and Endogenous FSH Levels After Multiple Dosing of FE Table 1 Summary of subject characteristics Mean (Range) Age (years) 31.1 ( ) Height (cm) ( ) Weight (kg) 71.5 ( ) BMI (kg/m 2 ) 26.6 ( ) FSH (lg/l) ( ) E2 (pg/ml) ( ) LH (IU/L) ( ) Prog (lg/l) ( ) InhB (pg/ml) 22.0 ( ) Demographics and measured baseline hormone levels for the 24 subjects receiving FE BMI body mass index, FSH follicle-stimulating hormone, E2 estradiol, LH luteinising hormone, Prog progesterone, InhB inhibin B errors are estimated. For parameters with IIV, the ith subject s individual parameter (h i ) is log-normally distributed: h i ¼ h expðg i Þ ð1þ where h is the typical population parameter and g i is the individual random effect from an approximately normal distribution with mean zero and variance x 2 for describing the IIV of the parameter. In the model, potential influential factors can be tested for significance as a covariate to explain some of the IIV in a parameter. Thus, the set of individual parameters (H i ) is given as a function of the typical population parameters (H) individual values of the covariates (c i ) and random effects (g i ): H i ¼ gðh; c i ; g i Þ ð2þ The residual errors (e) are assumed normally distributed with mean zero and variance r 2, and are the unexplained deviations of model predictions from the observations: y ij ¼ f t ij ; H i þ eij ð3þ where y ij is the observation at time t ij and the subscript ij denotes the jth number for subject i. The individual model prediction f ( ) at time t ij is calculated from the individual parameters (H i ). Model development was guided by changes in the NONMEM objective function value (OFV), precision of parameter estimates, and graphical model goodness-of-fit assessments, including visual predictive checks (VPC). In the VPC, the observed data are compared with model predictions based on 1000 simulated trial datasets using the final model. It displays the observations and the 2.5th, 50th, and 97.5th percentiles of observations, and the 95 % confidence intervals (CI) for the corresponding model predictions are plotted. The OFV is approximately proportional to -2log likelihood. The difference in OFV (dofv) between two nested models is approximately Chi square-distributed, with degrees of freedom (df) equal to the difference in the number of parameters. Based on this, the statistical significance for inclusion/exclusion of a model parameter can be judged. A significance level of 0.05 was used for discrimination among nested models and covariate testing, corresponding to a 3.84 change in OFV for 1 df. Measurable FSH levels before drug administration indicated that endogenous FSH was not fully suppressed in this trial. The total FSH amount at time t in the central compartment was therefore modelled as the sum of the endogenous FSH and the exogenously administered rhfsh (FE ): FSHðtÞ ¼FSH en ðþ+ t rhfshðþ t ð4þ The endogenous FSH was assumed to have the same elimination rate constant from the central compartment as FE ; thus, the total FSH is eliminated from the central compartment with rate constant k given by clearance (CL) divided by volume of distribution (V). Since data are obtained after subcutaneous dosing, the bioavailability (F) is not known. The CL and V estimated here are therefore the apparent CL (CL/F) and apparent V (V/F). The change in endogenous FSH amount over time in the central compartment was described as a turnover model with a zero-order production rate k in : dfsh en ðþ t ¼ k in k FSH en ðþ t ð5þ dt At time zero, before rhfsh dosing, the measured concentration in the central compartment is purely endogenous FSH. The endogenous FSH baseline concentrations (FSH bl ) for each subject can therefore be estimated as the initial concentration in the central compartment and is the initial condition for the differential equation for the central compartment FSH bl V/F, i.e. the individual endogenous FSH amount at baseline. When assuming steady state and hence zero change in the total FSH concentration before dosing, individual values of k in can be calculated from the other estimated parameters and baseline values. One- and two-compartment models were tested for describing the distribution of FE A lag-time and transit compartments were investigated for modelling a potential delay in the absorption process. Body weight, age, and hormone (estradiol, inhibin B, progesterone) values at baseline were tested as potential covariates, explaining some of the IIV in parameter estimates. Inhibin B was also tested as a covariate over time since it has a purely inhibitory effect on FSH. The measured hormone levels were assumed to not affect the rhfsh concentration, but only
4 168 T. H. Rose et al. tested as covariates on the endogenous FSH baseline parameter (FSH bl ). Besides a decrease in OFV, the significance of a covariate was also evaluated by looking at the reduction in the IIV, measured as a coefficient of variation (CV) for the parameter s random effect. 2.3 Software The models were implemented and parameters estimated in NONMEM (Icon Development Solutions, Ellicott City, MD, USA) [4]. Data handling and graphical representations were performed in R version [5]. VPCs were performed using PsN [6, 7] and plotted using Xpose [8]. 3 Results The best structural model was a one-compartment distribution model. The FE absorption was found to be delayed, and a one-compartment transit model best described the process. Endogenous FSH contributed significantly to the total FSH concentration in the central compartment. Observed inhibin B levels [InhB(t)] suppressed endogenous FSH production rate (k in ) over time when introduced in the model as a time-varying covariate. The relationship was found to be best described by an inhibitory E max model, also know as an I max function, expressed as a fractional inhibition with complete inhibition possible and a parameter InhB ef as the inhibin B concentration giving 50 % inhibition [see Eq. (8)]. The full compartment model is illustrated in Fig. 1 and the corresponding differential equations are as follows: drhfsh DS ðþ t ¼ k tr rhfsh DS ðþ t ð6þ dt drhfsh TR ðþ t ¼ k tr rhfsh DS ðþ k t a rhfsh TR ðþ t dt dfshðþ t ¼ k in dt InhBðtÞ 1 InhBðtÞþInhB ef rhfsh TR ðþ k t FSHðÞ t þ k a ð7þ ð8þ where rhfsh DS (t) and rhfsh TR (t) are the FE amounts at the dosing site and in the transit compartment, respectively, and k tr is the absorption rate from the dosing site to the transit compartment. Equation (8) describes the change in total FSH amount in the central compartment, with the endogenous FSH contribution as the first term. The exogenously administered rhfsh enters the central compartment with rate constant k a. IIV was introduced for CL/F, V/F, k tr, and FSH bl. The variances of the IIV on CL/F and V/F were positively correlated. Body weight was an allometrically scaled Fig. 1 Compartment diagram illustrating the pharmacokinetic model for FE with a contribution of endogenous FSH to the central compartment. FSH follicle-stimulating hormone, rhfsh recombinant human FSH, FSH en (t) endogenous FSH amount, InhB(t) inhibin B level, rhfsh TR (t) rhfsh amount in the transit compartment, FSH(t) total FSH amount in the central compartment, k in endogenous FSH production rate, k tr absorption rate from the dosing site, k a absorption rate from the transit compartment, k elimination rate covariate at CL/F and V/F, with the power exponents fixed to 0.75 and 1, respectively. Adding body weight as a covariate reduced CV for the unexplained IIV from 18.1 to 15.6 % CV for CL/F, and from 22.0 to 18.4 % CV for V/ F. A trend towards lower estimated FSH baseline levels was seen in individuals with higher progesterone baseline levels (Fig. 2). The progesterone baseline effect was confirmed to be a statistically significant covariate when modelled as an inhibitory power function at the FSH bl parameter. This decreased IIV in FSH bl from 32.6 to 27.8 % CV. A combined additive and proportional error model was used to describe the residual error. The final model parameter estimates are displayed in Table 2. The VPC plot (Fig. 3) based on 1000 simulations, shows that the model overall adequately predicts the FSH concentrations over time, with appropriate variation. The model also satisfactorily predicted the individual pharmacokinetic profile for each subject in the trial (Fig. 4). The typical population CL/F and V/F for a 65-kg woman were L/h and 24.3 L, respectively, giving an elimination rate of h -1 and a terminal half-life of 40 h. When the best
5 Population PK and Endogenous FSH Levels After Multiple Dosing of FE were lower than the observed baselines. Furthermore, accounting for inhibin B suppression of the endogenous FSH contribution over time increased the V/F estimate from 18.9 to 24.3 L. Not including inhibin B as a covariate in the final model resulted in an increase from 83.4 to % CV at k tr. 4 Discussion Fig. 2 The relationship between endogenous FSH and progesterone at baseline. Points are individual-predicted FSH bl values and observed progesterone baseline values with a smooth LOWESS trend line (broken line). The solid line is the power function used in the model describing the typical population relationship for the effect of progesterone baseline at the parameter FSH bl. FSH follicle-stimulating hormone, FSH b1 endogenous FSH baseline model was found in a forward development process, it was checked to see if all the elements were still significant or if the model could be reduced. Table 3 describes the resulting increase in OFV after removing the elements. No reduction was possible since the dofv was a minimum of 7 and up to 78. In order to see what difference accounting for endogenous FSH in the model makes, the individual concentration time profiles for the model-predicted endogenous FSH level were compared with when the observed endogenous FSH baseline was assumed to be constant throughout the trial (Fig. 5). Due to the suppression by observed InhB(t) over time, the predicted endogenous FSH levels The FE population pharmacokinetics have previously been characterised after single-dose administration using a one-compartment model. The results were in agreement with modelling results from the literature [2]. In accordance with those results, the current analysis showed that after multiple FE dosing, the population pharmacokinetics were also best described by a one-compartment model with first-order elimination and absorption through a transit compartment. A correlation between CL/ F and V/F was observed, and body weight was an allometrically scaled covariate for both CL/F and V/F. Hereby, it was confirmed that lower average steady-state drug exposure in females correlates with higher body weight after repeated doses, which is in agreement with singledose FE results. In contrast to the single-dose trial, FSH downregulation in this trial was not complete since a measurable endogenous FSH level was detected before any drug administration. The observed endogenous FSH contributes to total FSH measurements and thereby affects the evaluation of rhfsh concentrations in the trial; thus, it had to be accounted for in the model. To adjust the model accordingly, it was necessary to add an endogenous supply of FSH to the central compartment for proper prediction of the total FSH concentration. Table 2 Pharmacokinetic parameter estimates Parameter Estimate (RSE%) IIV CV% (RSE%) Shrinkage (%) CL/F (L/h) (3.9) 15.6 (12.7) V/F (L) (4.6) 18.4 (14.4) 2.80 k tr (h -1 ) (17.0) 83.4 (24.1) 24.6 k a (h -1 ) (13.2) FSH bl (lg/ (9.1) 27.8 (16.5) 5.51 L) Progbl ef (34.7) InhB ef 100 (37.2) Typical population parameter estimates obtained from modelling For CL/F and V/F the value is the typical value for a woman weighing 65 kg RSE relative standard error, IIV interindividual variability, CV coefficient of variation, F bioavailability, CL/F apparent clearance, V/F apparent volume of distribution, k tr absorption rate from the dosing site, k a absorption rate from the transit compartment, FSH bl endogenous follicle-stimulating hormone baseline, Progbl ef power exponent for progesterone baseline covariate effect, InhB ef inhibin B time-varying covariate effect
6 170 T. H. Rose et al. Table 3 Change in objective function value for reduced models Removing df dofv WT at V/F WT at CL/F WT at CL/F and V/F cov (CL/F, V/F) Progesterone effect Inhibin B effect The resulting dofv when removing covariates or the correlation between CL/F and V/F [cov(cl/f,v/f)] F bioavailability, CL/F apparent clearance, V/F apparent volume of distribution, WT body weight, df degrees of freedom, dofv difference in objective function value Fig. 3 Visual predictive check for the final model, showing the individual observed FSH concentrations (points) and the 2.5th, 50th, and 97.5th percentiles of observations (lines). The shaded areas are the 95 % confidence intervals for the 2.5th, 50th, and 97.5th percentiles of the simulations. FSH follicle-stimulating hormone When evaluating the pharmacokinetics of drugs that are naturally occurring substances, data are often baseline corrected in order to get values representing only the exogenously administered drug. However, when dealing with hormones, fluctuations from the endogenous baseline value over time may be observed due to various feedback control systems. Even with gonadotropin downregulation, the endogenous FSH level will most likely change over time as progesterone, inhibin B, and estradiol exert inhibitory and stimulatory feedback loops at the production and release of gonadotropins. The potential impact of varying endogenous FSH levels at the pharmacokinetic assessment of FE was tested by incorporating different covariate relationships in the model. Before any drug was administered, there was a tendency towards a decreased endogenous FSH baseline with increasing progesterone baseline. A power function for the relation between progesterone baseline and FSH bl was shown to be significantly better than using a linear, an exponential, or an I max function. When introduced as a time-varying covariate, inhibin B was found to suppress the endogenous FSH production rate over time, with an I max function being the Fig. 4 Individual model fit with observed (points) and predicted (lines) total FSH concentrations versus time. The number at each subplot is the subject identification number. FSH follicle-stimulating hormone
7 Population PK and Endogenous FSH Levels After Multiple Dosing of FE Fig. 5 Individual hormone concentration profiles over time. The broken blue line indicates the observed endogenous FSH baseline level when assuming it to be constant throughout the trial, and the solid blue line is the model-predicted endogenous FSH level when accounting for the suppression caused by the observed inhibin B levels (purple line) over time, as identified by the model. The number at each subplot is the subject identification number. FSH follicle-stimulating hormone most significant relationship. When accounting for the inhibitory effect of inhibin B over time, the resulting model-predicted endogenous FSH concentration profiles indicated that the observed FSH baseline is an overestimate of the endogenous FSH level at all time points other than zero (Fig. 5). As a consequence, the drug concentration would be underestimated if the data were baseline corrected. When multiple covariates and correlations have been added to the model, it is possible that initial significant relations have become redundant and hence can be removed from the model. It was therefore checked whether the model could be reduced. Removing any relations resulted in an increase in OFV, and thus all relations were still significant. Removing body weight from both CL/ F and V/F increased OFV less than removing body weight from only one of these parameters, which could be due to the fact that there is a correlation between the two parameters. The population pharmacokinetic parameters estimated with nonlinear mixed-effect modelling for single and multiple doses of FE are similar. In the modelling of single-dose data, CL/F and V/F for a 65 kg woman were found to be L/h and 28.0 L, respectively [2], with a resulting terminal half-life of 45 h. In this trial, CL/F was L/h and V/F was 24.3 L. By incorporating the inhibin B dynamics into the model, and suppressing the endogenous FSH contribution instead of letting the FSH baseline be constant throughout the trial, V/F increased from 18.9 to 24.3 L, suggesting that without proper estimation of endogenous FSH levels over time a bias in V/ F may be obtained. The terminal half-life in the current analysis was estimated to be 40 h, thus slightly shorter than the 45 h reported after single-dose administration. The phenomenon of shorter half-life after repeated subcutaneous dosing compared with single administration was also observed using NCA-based methods for analysing different FE datasets, but could not be further explained [3]. The CL/F for other rfsh products has been found to be 0.99 L/h [3] and 0.71 L/h [9]; thus, our estimated CL/F for FE is consistently lower. Furthermore, the terminal half-life of FE is longer than reported values in the literature for repeated subcutaneous dosing of rfsh products, which is approximately 24 h [3, 10]. In the same studies, a longer terminal half-life has been reported after single subcutaneous dosing (34.5 [3] and 27 h [10]). One study [11] found a terminal half-life of 59 h after single subcutaneous dosing of 115 IU rfsh; however, they noted that the estimate was not reliable since the low dose only gave a concentration slightly over baseline. This work shows that when subjects have measurable endogenous FSH levels, total FSH concentration is affected, and the endogenous FSH level varies over time as a consequence of the feedback from ovarian hormones. If not accounting for this in the model, the pharmacokinetic parameter estimates can be biased. The inclusion of endogenous hormones in the model might be even more important in the target patient group since they are likely to have higher endogenous FSH baseline levels as they will not be pituitary downregulated or suppressed. In addition, the variation in endogenous FSH levels over time could be very different between patients due to their different types
8 172 T. H. Rose et al. of infertility, which might affect the reproductive hormone dynamics differently. Characterising the endogenous FSH level and considering the hormone dynamics is therefore important as it could have clinical relevance for the dose needed. In summary, this early characterisation of FE population pharmacokinetics after repeated dosing is in line with previously reported findings of rhfsh population pharmacokinetics after single-dose administration. The results provide a basis for study design and data evaluation considerations in the future development of rfsh products. The standard method of baseline-correcting data for rfsh products has been questioned since the model indicates that endogenous FSH significantly affects the total FSH concentration and varies over time. 5 Conclusions The multiple-dose FE population pharmacokinetics were in agreement with results obtained after singledose administration [2]. It was confirmed that after repeated drug administration, FE exposure also appears lower in females with a higher body weight. These findings add to the evidence of body weight being an important factor in designing individualised dosing schemes. This analysis indicates that the inclusion of endogenous FSH levels and quantifying the influence of the reproductive hormone dynamics at the endogenous FSH level over time may well be essential for proper estimation of the pharmacokinetic parameters for FSH preparations. The standard method of baseline-correcting data does not account for a variation during the trial and could potentially cause an underestimation of serum drug concentration and hence inaccurate parameter estimation. To better explore and link the time-varying impact of inhibin B on endogenous FSH levels, a more mechanistic modelling approach may be warranted for including indirect delayed response and hormone feedback mechanisms in a pharmacokinetic pharmacodynamic model, and simultaneously quantifying the inhibin B response to rhfsh stimulation. The relevance of endogenous hormone levels should also be related to other pharmacodynamic and clinical endpoints in order to establish its significance. Compliance with Ethical Standards Funding This work was supported by Innovation Fund Denmark (Industrial PhD Case Number ). Conflict of interest Trine Høyer Rose, Daniel Röshammar, Lars Erichsen, and Lars Grundemar are all current or former employees of Ferring Pharmaceuticals A/S. Johnny T. Ottesen has no conflicts of interest to declare. Ethical approval All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and/or national research committee and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards. Informed consent Informed consent was obtained from all individual participants included in the study. Open Access This article is distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 International License ( which permits any noncommercial use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. References 1. Macklon NS, Stouffer RL, Giudice LC, Fauser BC. The science behind 25 years of ovarian stimulation for in vitro fertilization. Endocr Rev. 2006;27: Rose TH, Röshammar D, Erichsen L, Grundemar L, Ottesen JT. Population pharmacokinetic modelling of FE , a recombinant human follicle-stimulating hormone, in healthy women after single ascending doses. Drugs R D doi: / s Olsson H, Sandström R, Grundemar L. Different pharmacokinetic and pharmacodynamic properties of recombinant follicle-stimulating hormone (rfsh) derived from a human cell line compared with rfsh from a non-human cell line. J Clin Pharmacol. 2014;54: Beal S, Sheiner LB, Boeckmann A, Bauer RJ. NONMEM user s guides ( ). Ellicott City: Icon Development Solutions; R Development Core Team. R: a language and environment for statistical computing. Vienna: R Foundation for Statistical Computing; Lindbom L, Ribbing J, Jonsson EN. Perl-speaks-NONMEM (PsN): a Perl module for NONMEM related programming. Comput Methods Programs Biomed. 2004;75: Lindbom L, Pihlgren P, Jonsson EN. PsN-Toolkit: a collection of computer intensive statistical methods for non-linear mixed effect modeling using NONMEM. Comput Methods Programs Biomed. 2005;79: Jonsson EN, Karlsson MO. Xpose an s-plus based population pharmacokinetic/pharmacodynamic model building aid for nonmem. Comput Methods Programs Biomed. 1999;58: Karlsson MO, Wade JR, Loumaye E, Munafo A. The population pharmacokinetics of recombinant- and urinary-human follicle stimulating hormone in women. Br J Clin Pharmacol. 1998;45: le Cotonnec JY, Porchet HC, Beltrami V, Khan A, Toon S, Rowland M. Clinical pharmacology of recombinant human follicle-stimulating hormone. II: single doses and steady state pharmacokinetics. Fertil Steril. 1994;61: le Cotonnec JY, Loumaye E, Porchet HC, Beltrami V, Munafo A. Pharmacokinetic and pharmacodynamic interactions between recombinant human luteinizing hormone and recombinant human follicle-stimulating hormone. Fertil Steril. 1998;69:201 9.
Title: Authors: Journal:
IMPORTANT COPYRIGHT NOTICE: This electronic article is provided to you by courtesy of Ferring Pharmaceuticals. The document is provided for personal usage only. Further reproduction and/or distribution
Impact of patient characteristics on the pharmacokinetics of corifollitropin alfa during controlled ovarian stimulation
British Journal of Clinical Pharmacology PHARMACOKINETICS Br J Clin Pharmacol (2016) 82 74 82 74 Impact of patient characteristics on the pharmacokinetics of corifollitropin alfa during controlled ovarian
Agonist versus antagonist in ICSI cycles: a randomized trial and cost effectiveness analysis Badrawi A, Zaki S, Al-Inany H, Ramzy A M, Hussein M
Agonist versus antagonist in ICSI cycles: a randomized trial and cost effectiveness analysis Badrawi A, Zaki S, Al-Inany H, Ramzy A M, Hussein M Record Status This is a critical abstract of an economic
LH activity administration during the
LH activity administration during the luteal-follicular transition Richard Fleming On behalf of the Luveris Pre-treatment group University of Glasgow Scotland Androgens have a Paracrine action in the Early
Antiviral Therapy 2012; 17:25 33 (doi: /IMP1915)
Antiviral Therapy 202; 7:25 33 (doi: 0.385/IMP95) Original article Population pharmacokinetics of lopinavir and ritonavir in combination with rifampicin-based antitubercular treatment in HIV-infected children
Draft Agreed by Biosimilar Working Party (BMWP) October Adoption by CHMP for release for consultation 17 November 2011
1 2 3 17 November 2011 EMA/CHMP/BMWP/671292/2010 Committee for Medicinal Products for Human Use (CHMP) 4 5 6 7 Guideline on non-clinical and clinical development of similar biological medicinal products
Clinical Study Clinical Effects of a Natural Extract of Urinary Human Menopausal Gonadotrophin in Normogonadotropic Infertile Patients
International Reproductive Medicine Volume 2013, Article ID 135258, 4 pages http://dx.doi.org/10.1155/2013/135258 Clinical Study Clinical Effects of a Natural Extract of Urinary Human Menopausal Gonadotrophin
SYNOPSIS. The study results and synopsis are supplied for informational purposes only.
SYNOPSIS INN : LEFLUNOMIDE Study number : HMR486/1037 et HMR486/3503 Study title : Population pharmacokinetics of A77 1726 (M1) after oral administration of leflunomide in pediatric subjects with polyarticular
Reproductive Hormones
Reproductive Hormones Male gonads: testes produce male sex cells! sperm Female gonads: ovaries produce female sex cells! ovum The union of male and female sex cells during fertilization produces a zygote
Female Reproductive Physiology. Dr Raelia Lew CREI, FRANZCOG, PhD, MMed, MBBS Fertility Specialist, Melbourne IVF
Female Reproductive Physiology Dr Raelia Lew CREI, FRANZCOG, PhD, MMed, MBBS Fertility Specialist, Melbourne IVF REFERENCE Lew, R, Natural History of ovarian function including assessment of ovarian reserve
LOW RESPONDERS. Poor Ovarian Response, Por
LOW RESPONDERS Poor Ovarian Response, Por Patients with a low number of retrieved oocytes despite adequate ovarian stimulation during fertility treatment. Diagnosis Female About Low responders In patients
The legally binding text is the original French version TRANSPARENCY COMMITTEE OPINION. 22 September 2010
The legally binding text is the original French version TRANSPARENCY COMMITTEE OPINION 22 September 2010 100 µg/0.5 ml, solution for injection B/1 prefilled syringe + 1 needle (CIP code: 374 590-1) 150
An integrated glucose-insulin model to describe oral glucose tolerance test data in healthy volunteers
Title: An integrated glucose-insulin model to describe oral glucose tolerance test data in healthy volunteers Authors: Hanna E. Silber 1, Nicolas Frey 2 and Mats O. Karlsson 1 Address: 1 Department of
Luteal phase rescue after GnRHa triggering Progesterone and Estradiol
Luteal phase rescue after GnRHa triggering Progesterone and Estradiol L. Engmann University of Connecticut Disclaimer Fertility Speaker Bureau Merck Pharmaceuticals Introduction GnRH agonist is effective
REPRODUCCIÓN. La idea fija. Copyright 2004 Pearson Education, Inc., publishing as Benjamin Cummings
REPRODUCCIÓN La idea fija How male and female reproductive systems differentiate The reproductive organs and how they work How gametes are produced and fertilized Pregnancy, stages of development, birth
IVF (,, ) : (HP-hMG) - (IVF- ET) : GnRH, HP-hMG (HP-hMG )57, (rfsh )140, (Gn)
34 11 Vol.34 No.11 2014 11 Nov. 2014 Reproduction & Contraception doi: 10.7669/j.issn.0253-3X.2014.11.0892 E-mail: randc_journal@163.com IVF ( 710003) : (H-hMG) - (IVF- ET) : GnRH H-hMG (H-hMG ) (rfsh
10.7 The Reproductive Hormones
10.7 The Reproductive Hormones December 10, 2013. Website survey?? QUESTION: Who is more complicated: men or women? The Female Reproductive System ovaries: produce gametes (eggs) produce estrogen (steroid
Title: Authors: Journal:
IMPORTANT COPYRIGHT NOTICE: This electronic article is provided to you by courtesy of Ferring Pharmaceuticals. The document is provided for personal usage only. Further reproduction and/or distribution
Case Study in Placebo Modeling and Its Effect on Drug Development
Case Study in Placebo Modeling and Its Effect on Drug Development Modeling and Simulation Strategy for Phase 3 Dose Selection of Dasotraline in Patients With Attention-Deficit/Hyperactivity Disorder Julie
PDF hosted at the Radboud Repository of the Radboud University Nijmegen
PDF hosted at the Radboud Repository of the Radboud University Nijmegen The following full text is a publisher's version. For additional information about this publication click this link. http://hdl.handle.net/2066/24875
I. ART PROCEDURES. A. In Vitro Fertilization (IVF)
DFW Fertility Associates ASSISTED REPRODUCTIVE TECHNOLOGY (ART) Welcome to DFW Fertility Associates/ Presbyterian-Harris Methodist Hospital ARTS program. This document provides an overview of treatment
REPRODUCTION & GENETICS. Hormones
REPRODUCTION & GENETICS Hormones http://www.youtube.com/watch?v=np0wfu_mgzo Objectives 2 Define what hormones are; Compare and contrast the male and female hormones; Explain what each hormone in the mail
The effect of adding oral oestradiol to progesterone as luteal phase support in ART cycles a randomized controlled study
Clinical research The effect of adding oral oestradiol to progesterone as luteal phase support in ART cycles a randomized controlled study Ashraf Moini 1,2, Shahrzad Zadeh Modarress 3, Elham Amirchaghmaghi
The reproductive lifespan
The reproductive lifespan Reproductive potential Ovarian cycles Pregnancy Lactation Male Female Puberty Menopause Age Menstruation is an external indicator of ovarian events controlled by the hypothalamicpituitary
Clinical Policy: Infertility Therapy Reference Number: CP.CPA.261 Effective Date: Last Review Date: Line of Business: Medicaid Medi-Cal
Clinical Policy: Reference Number: CP.CPA.261 Effective Date: 11.16.16 Last Review Date: 11.17 Line of Business: Medicaid Medi-Cal Revision Log See Important Reminder at the end of this policy for important
Chapter 27 The Reproductive System. MDufilho
Chapter 27 The Reproductive System 1 Figure 27.19 Events of oogenesis. Before birth Meiotic events 2n Oogonium (stem cell) Mitosis Follicle development in ovary Follicle cells Oocyte 2n Primary oocyte
Population Pharmacokinetics of Cladribine in Patients with Multiple Sclerosis
Clin Pharmacokinet (2017) 56:1245 1253 DOI 10.1007/s40262-017-0516-6 ORIGINAL RESEARCH ARTICLE Population Pharmacokinetics of Cladribine in Patients with Multiple Sclerosis Radojka M. Savic 1 Ana M. Novakovic
ENDOCRINE CHARACTERISTICS OF ART CYCLES
ENDOCRINE CHARACTERISTICS OF ART CYCLES DOÇ. DR. SEBİHA ÖZDEMİR ÖZKAN KOCAELI UNIVERSITY, SCHOOL OF MEDICINE, DEPARTMENT OF OBSTETRICS AND GYNECOLOGY, IVF UNIT 30.04.2014, ANTALYA INTRODUCTION The endocrine
Milder is better? Advantages and disadvantages of "mild" ovarian stimulation for human in vitro fertilization
Milder is better? Advantages and disadvantages of "mild" ovarian stimulation for human in vitro fertilization Revelli et al. Reproductive Biology and Endocrinology 2011, 9:25 Presenter: R2 孫怡虹 Background
Female Reproductive System. Lesson 10
Female Reproductive System Lesson 10 Learning Goals 1. What are the five hormones involved in the female reproductive system? 2. Understand the four phases of the menstrual cycle. Human Reproductive System
Hormonal Control of Human Reproduction
Hormonal Control of Human Reproduction Bởi: OpenStaxCollege The human male and female reproductive cycles are controlled by the interaction of hormones from the hypothalamus and anterior pituitary with
SISTEMA REPRODUCTOR (LA IDEA FIJA) Copyright 2004 Pearson Education, Inc., publishing as Benjamin Cummings
SISTEMA REPRODUCTOR (LA IDEA FIJA) How male and female reproductive systems differentiate The reproductive organs and how they work How gametes are produced and fertilized Pregnancy, stages of development,
9.4 Regulating the Reproductive System
9.4 Regulating the Reproductive System The Reproductive System to unite a single reproductive cell from a female with a single reproductive cell from a male Both male and female reproductive systems include
Does previous response to clomifene citrate influence the selection of gonadotropin dosage given in subsequent superovulation treatment cycles?
J Assist Reprod Genet (26) 23:427 431 DOI 1.17/s1815-6-965-x ASSISTED REPRODUCTION Does previous response to clomifene citrate influence the selection of gonadotropin dosage given in subsequent superovulation
1. During the follicular phase of the ovarian cycle, the hypothalamus releases GnRH.
1. During the follicular phase of the ovarian cycle, the hypothalamus releases GnRH. 2. This causes the anterior pituitary to secrete small quantities of FSH and LH. 3. At this time, the follicles in the
Chapter 14 Reproduction Review Assignment
Date: Mark: _/45 Chapter 14 Reproduction Review Assignment Multiple Choice Identify the choice that best completes the statement or answers the question. 1. Use the diagram above to answer the next question.
Can cycle day 7 FSH concentration during controlled ovarian stimulation be used to guide FSH dosing for in vitro fertilization?
Bentov et al. Reproductive Biology and Endocrinology 2013, 11:12 RESEARCH Open Access Can cycle day 7 FSH concentration during controlled ovarian stimulation be used to guide FSH dosing for in vitro fertilization?
AUSTRALIAN PRODUCT INFORMATION ORGALUTRAN (ganirelix acetate) Solution for Injection
AUSTRALIAN PRODUCT INFORMATION ORGALUTRAN (ganirelix acetate) Solution for Injection 1 NAME OF THE MEDICINE Ganirelix acetate 2 QUALITATIVE AND QUANTITATIVE COMPOSITION Orgalutran 250 µg ganirelix (as
Endocrinology of the Female Reproductive Axis
Endocrinology of the Female Reproductive Axis girlontheriver.com Geralyn Lambert-Messerlian, PhD, FACB Professor Women and Infants Hospital Alpert Medical School at Brown University Women & Infants BROWN
Manish Banker. Declared receipt of grants; member of a company advisory board, board of director or similar group
Manish Banker Nova IVI Fertility Pulse Women's Hospital Gujarat, India Declared receipt of grants; member of a company advisory board, board of director or similar group The Indian point of view Manish
Clinical profiling of recombinant follicle stimulating hormone (rfsh; Puregon): relationship between serum FSH and efficacy
Human Reproduction Update 1996, Vol. 2, No. 2 pp. 153 161 European Society for Human Reproduction and Embryology Clinical profiling of recombinant follicle stimulating hormone (rfsh; Puregon): relationship
Two important cells in female are the theca cells and the granulose cells. Granulosa cells are affected by the two gonadotropin hormones; FSH and LH.
1 UGS physiology sheet #13 lecture 3 Dr.Saleem Khresha. Now we will start discussing the female reproductive system Ovarian Steroids Two important cells in female are the theca cells and the granulose
HCG mode of action versus GnRHa action for triggering of final oocyte maturation
HCG mode of action versus GnRHa action for triggering of final oocyte maturation Nick Macklon Professor of Obstetrics and Gynaecology, University of Southampton A hammer to crack a nut hcg? How hard does
Pharmacokinetics and allometric scaling of levormeloxifene, a selective oestrogen receptor modulator
BIOPHARMACEUTICS & DRUG DISPOSITION Biopharm. Drug Dispos. 24: 121 129 (2003) Published online in Wiley InterScience (www.interscience.wiley.com). DOI: 10.1002/bdd.344 Pharmacokinetics and allometric scaling
A Case of Pregnancy Using Recombinant Follicle Stimulating Hormone and Gonadotropin Releasing Hormone Antagonist
1 *, ** * * * ** A Case of Pregnancy Using Recombinant Follicle Stimulating Hormone and Gonadotropin Releasing Hormone Antagonist Yoon Sung Nam, Nam Keun Kim*, Eun Kyung Kim**, Hyung Min Chung** and Kwang
MULTIPLE CHOICE: match the term(s) or description with the appropriate letter of the structure.
Chapter 27 Exam Due NLT Thursday, July 31, 2015 Name MULTIPLE CHOICE: match the term(s) or description with the appropriate letter of the structure. Figure 27.1 Using Figure 27.1, match the following:
An imputation-based method to reduce bias in model parameter estimates due to non-random censoring in oncology trials
TCP 2016;24(4):189-193 http://dx.doi.org/10.12793/tcp.2016.24.4.189 An imputation-based method to reduce bias in model parameter estimates due to non-random censoring in oncology trials Dongwoo Chae 1,2
Reproductive FSH. Analyte Information
Reproductive FSH Analyte Information 1 Follicle-stimulating hormone Introduction Follicle-stimulating hormone (FSH, also known as follitropin) is a glycoprotein hormone secreted by the anterior pituitary
ANNEX I SUMMARY OF PRODUCT CHARACTERISTICS
ANNEX I SUMMARY OF PRODUCT CHARACTERISTICS IV 1. NAME OF THE MEDICINAL PRODUCT Puregon 2. QUALITATIVE AND QUANTITATIVE COMPOSITION Puregon 50 I.U. consists of a freeze-dried powder and a solvent for reconstitution.
PRODUCT INFORMATION. Pharmacotherapeutic group: anti-gonadotrophin releasing hormone; ATC code: H01CC01.
Orgalutran PRODUCT INFORMATION (i) NAME OF THE MEDICINE Orgalutran 250 mg/0.5 ml solution for injection Orgalutran contains the synthetic decapeptide ganirelix (INN) as its acetate salt, with high antagonistic
Investigation: The Human Menstrual Cycle Research Question: How do hormones control the menstrual cycle?
Investigation: The Human Menstrual Cycle Research Question: How do hormones control the menstrual cycle? Introduction: The menstrual cycle (changes within the uterus) is an approximately 28-day cycle that
Elonva (corifollitropin alfa): A simplified, patientfocused
Product Monograph (corifollitropin alfa): A simplified, patientfocused approach to controlled ovarian stimulation TABLE OF CONTENTS (corifollitropin alfa): A simplified, patientfocused approach to controlled
Orgalutran 0.25 mg/0.5 ml solution for injection 2. QUALITATIVE AND QUANTITATIVE COMPOSITION
1 1. NAME OF THE MEDICINAL PRODUCT 0.25 mg/0.5 ml solution for injection 2. QUALITATIVE AND QUANTITATIVE COMPOSITION Each pre-filled syringe contains 0.25 mg of ganirelix (INN) in 0.5 mg aqueous solution.
Bioequivalence of subcutaneous injections of recombinant human follicle stimulating hormone (Puregon ) by Pen-injector and syringe
Human Reproduction vol.14 no.7 pp.1698 1702, 1999 Bioequivalence of subcutaneous injections of recombinant human follicle stimulating hormone (Puregon ) by Pen-injector and syringe Gerrit Voortman 1,3,
PK/PD modeling and optimization of eltrombopag dose and regimen for treatment of chemotherapy- induced thrombocytopenia in cancer patients
PAGE 2012 PK/PD modeling and optimization of eltrombopag dose and regimen for treatment of chemotherapy- induced thrombocytopenia in cancer patients S. Hayes 1, P. N. Mudd Jr 2, D. Ouellet 2, E. Gibiansky
08036-Barcelona, Spain. Fax: ;
RBMOnline - Vol 6. No 4. 427 431 Reproductive BioMedicine Online; www.rbmonline.com/article/859 on web 13 March 2003 Article Pregnancy after administration of high dose recombinant human LH alone to support
Population pharmacokinetic and pharmacodynamic analyses of safinamide in subjects with Parkinson s disease
ORIGINAL ARTICLE Population pharmacokinetic and pharmacodynamic analyses of safinamide in subjects with Parkinson s disease Luca Loprete 1, Chiara Leuratti 2, Carlo Cattaneo 3, Mita M. Thapar 4, Colm Farrell
Principles of Ovarian Stimulation
Principles of Ovarian Stimulation Dr Genia Rozen Gynaecologist and Fertility Specialist Royal Women s Hospital and Melbourne IVF Learning objectives Why ovarian stimulation Recap physiology Ovarian cycle
Neil Goodman, MD, FACE
Initial Workup of Infertile Couple: Female Neil Goodman, MD, FACE Professor of Medicine Voluntary Faculty University of Miami Miller School of Medicine Scope of Infertility in the United States Affects
Article Luteal hormonal profile of oocyte donors stimulated with a GnRH antagonist compared with natural cycles
RBMOnline - Vol 13. No 3. 2006 326 330 Reproductive BioMedicine Online; www.rbmonline.com/article/1911 on web 13 June 2006 Article Luteal hormonal profile of oocyte donors stimulated with a GnRH antagonist
Effects of HCG and LH on ovarian stimulation. Are they bioequivalent?
Effects of HCG and LH on ovarian stimulation Are they bioequivalent? Know the type of gonadotrophin required to have enough oocytes of good quality to achieve a healthy child FSH MAXIMIZE EFFICIENCY MINIMIZE
A mild strategy in IVF results in favourable outcomes in terms of term live birth, cost and patient discomfort
Chapter 6 A mild strategy in IVF results in favourable outcomes in terms of term live birth, cost and patient discomfort Heijnen E.M., Eijkemans M.J., De Klerk C., Polinder S., Beckers N.G., Klinkert E.R.,
Cigna Drug and Biologic Coverage Policy
Cigna Drug and Biologic Coverage Policy Subject Infertility Injectables Table of Contents Coverage Policy... 1 General Background...16 Coding/Billing Information...20 References...20 Effective Date...
REPRODUCTION The diagram below shows a section through seminiferous tubules in a testis.
1. The diagram below shows a section through seminiferous tubules in a testis. Which cell produces testosterone? 2. A function of the interstitial cells in the testes is to produce A sperm B testosterone
Fertility Diagnostics
Fertility Diagnostics Fertility hormones measured on PATHFAST For internal use only Diagnostics PATHFAST Chemiluminescence-immuno-analyzer 1 Content: page 1. Fertility hormones - general aspects 1.1 Reproductive
Pharmacokinetic-Pharmacodynamic Modeling of the D 2 and 5-HT 2A Receptor Occupancy of Risperidone and Paliperidone in Rats
Pharm Res (2012) 29:1932 1948 DOI 10.1007/s11095-012-0722-8 RESEARCH PAPER Pharmacokinetic-Pharmacodynamic Modeling of the D 2 and 5-HT 2A Receptor Occupancy of Risperidone and Paliperidone in Rats Magdalena
Does triggering ovulation by 5000 IU of uhcg affect ICSI outcome? *
Middle East Fertility Society Journal Vol. 11, No. 2, 2006 Copyright Middle East Fertility Society Does triggering ovulation by 5000 IU of uhcg affect ICSI outcome? * Amany A.M. Shaltout, M.D. Mohamed
Population pharmacokinetic analysis of metformin administered as fixed-dose combination in Korean healthy adults
TCP 2018;26(1):25-31 2018;26(1):01-48 http://dx.doi.org/10.12793/tcp.2018.26.1.25 http://dx.doi.org/10.12793/tcp.2018.26.1.xx Population pharmacokinetic analysis of metformin administered as fixed-dose
A Tale of Three Hormones: hcg, Progesterone and AMH
A Tale of Three Hormones: hcg, Progesterone and AMH Download the Ferring AR ipad/iphone app from the Apple Store: http://bit.ly/1okk74m Human Ovarian Steroidogenesis and Gonadotrophin Stimulation Johan
Drug Therapy Guidelines
Drug Therapy Guidelines Applicable Injectable Fertility Medications: Bravelle, Cetrotide, Follistim AQ, Ganirelix, Gonal-F, human chorionic gonadotropin, leuprolide, Menopur, Novarel, Ovidrel, Pregnyl,
HCG (human chorionic gonadotropin); Novarel Pregnyl (chorionic gonadotropin); Ovidrel (choriogonadotropin alfa)
Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.08.09 Subject: HCG Page: 1 of 5 Last Review Date: June 19, 2015 HCG Powder, Novarel, Pregnyl, Ovidrel
A Tale of Three Hormones: hcg, Progesterone and AMH
A Tale of Three Hormones: hcg, Progesterone and AMH Download the Ferring AR ipad/iphone app from the Apple Store: http://bit.ly/1okk74m Interpreting Follicular Phase Progesterone Ernesto Bosch IVI Valencia,
Drug Therapy Guidelines
Drug Therapy Guidelines Applicable Medical Benefit Effective: 8/15/18 Pharmacy- Formulary 1 x Next Review: 6/18 Pharmacy- Formulary 2 x Date of Origin: 7/00 Injectable Fertility Medications: Bravelle,
lbt lab tests t Conrolled Ovarian Hyperstimulation Dr Soheila Ansaripour
lbt lab tests t and Conrolled Ovarian Hyperstimulation Dr Soheila Ansaripour Research Instituteof Avicenna 4/23/2012 Why good prediction of poor response good prediction i of OHSS application appropriate
The Human Menstrual Cycle
The Human Menstrual Cycle Name: The female human s menstrual cycle is broken into two phases: the Follicular Phase and the Luteal Phase. These two phases are separated by an event called ovulation. (1)
www.iffs-reproduction.org @IntFertilitySoc Int@FedFertilitySoc Conflict of interest none Outline Causes of ovulatory dysfunction Assessment of women with ovulatory dysfunction Management First line Second
Sarem et al. Sarem et al. Theoretical Biology and Medical Modelling 2014, 11:39
Bayesian approach for the estimation of cyclosporine area under the curve using limited sampling strategies in pediatric hematopoietic stem cell transplantation Sarem et al. Sarem et al. Theoretical Biology
Evaluation of a Scenario in Which Estimates of Bioequivalence Are Biased and a Proposed Solution: t last (Common)
Drug Development Evaluation of a Scenario in Which Estimates of Bioequivalence Are Biased and a Proposed Solution: t last (Common) The Journal of Clinical Pharmacology 2016, 56(7) 794 800 C 2015, The Authors.
Biology of fertility control. Higher Human Biology
Biology of fertility control Higher Human Biology Learning Intention Compare fertile periods in females and males What is infertility? Infertility is the inability of a sexually active, non-contracepting
N. Shirazian, MD. Endocrinologist
N. Shirazian, MD Internist, Endocrinologist Inside the ovary Day 15-28: empty pyfollicle turns into corpus luteum (yellow body) Immature eggs Day 1-13: 13: egg developing inside the growing follicle Day
Tutorial. & In case studies 1 and 2, we explore intravenous iv. & Then, we move on to extravascular dosing in case
The AAPS Journal, Vol. 1, No. 1, January 2016 ( # 2015) DOI: 10.120/s1224-015-917-6 Tutorial Pattern Recognition in Pharmacokinetic Data Analysis Johan Gabrielsson, 1,4 Bernd Meibohm, 2 and Daniel Weiner
ANNEX I SUMMARY OF PRODUCT CHARACTERISTICS
ANNEX I SUMMARY OF PRODUCT CHARACTERISTICS 1 This medicinal product is subject to additional monitoring. This will allow quick identification of new safety information. Healthcare professionals are asked
Personalizing ovarian stimulation for IVF
Personalizing ovarian stimulation for IVF Biljana Popovic-Todorovic MD,PhD Centre for Reproductive Medicine UZ Brussel QuickTime and are needed to see this picture. Controlled ovarian stimulation for IVF/ICSI
Chapter 14 The Reproductive System
Biology 12 Name: Reproductive System Per: Date: Chapter 14 The Reproductive System Complete using BC Biology 12, page 436-467 14. 1 Male Reproductive System pages 440-443 1. Distinguish between gametes
Pharmacometric Modelling to Support Extrapolation in Regulatory Submissions
Pharmacometric Modelling to Support Extrapolation in Regulatory Submissions Kristin Karlsson, PhD Pharmacometric/Pharmacokinetic assessor Medical Products Agency, Uppsala,Sweden PSI One Day Extrapolation
Phases of the Ovarian Cycle
OVARIAN CYCLE An ovary contains many follicles, and each one contains an immature egg called an oocyte. A female is born with as many as 2 million follicles, but the number is reduced to 300,000 to 400,000
Multilevel analysis quantifies variation in the experimental effect while optimizing power and preventing false positives
DOI 10.1186/s12868-015-0228-5 BMC Neuroscience RESEARCH ARTICLE Open Access Multilevel analysis quantifies variation in the experimental effect while optimizing power and preventing false positives Emmeke
Basic Pharmacokinetics and Pharmacodynamics: An Integrated Textbook with Computer Simulations
Basic Pharmacokinetics and Pharmacodynamics: An Integrated Textbook with Computer Simulations Rosenbaum, Sara E. ISBN-13: 9780470569061 Table of Contents 1 Introduction to Pharmacokinetics and Pharmacodynamics.
Ivf day 6 estradiol level
Ivf day 6 estradiol level Search It is also important to measure the estradiol on day 3. Day 2 is fine. The reason its day 3 is 15-20 years ago, the IVF medications were always started on day 3. Day 3
Saliva Versus Plasma Bioequivalence of Rusovastatin in Humans: Validation of Class III Drugs of the Salivary Excretion Classification System
Drugs R D (2015) 15:79 83 DOI 10.1007/s40268-015-0080-1 ORIGINAL RESEARCH ARTICLE Saliva Versus Plasma Bioequivalence of Rusovastatin in Humans: Validation of Class III Drugs of the Salivary Excretion
A differential equation model to investigate the dynamics of the bovine estrous cycle
A differential equation model to investigate the dynamics of the bovine estrous cycle H. M. T. Boer 1,2, C. Stötzel 3, S. Röblitz 3, H. Woelders 1 1 Animal Breeding and Genomics Centre, Wageningen UR Livestock
Dr. Ernesto Bosch Instituto Valenciano de Infertilidad Valencia, Spain. Declared no potential conflict of interest
Dr. Ernesto Bosch Instituto Valenciano de Infertilidad Valencia, Spain Declared no potential conflict of interest Is there a role for LH in elderly patients? Dr. Ernesto Bosch Instituto Valenciano de Infertilidad.
Ignacio Cortínez Anesthesiology Department School of Medicine, Pontificia Universidad Católica de Chile
Recommended doses of Levobupivacaine for TAP Blocks: Development of a pharmacokinetic model and estimation of the risk of symptoms of local anesthetic systemic toxicity Ignacio Cortínez Anesthesiology
LH (Bovine) ELISA Kit
LH (Bovine) ELISA Kit Catalog Number KA2280 96 assays Version: 05 Intended for research use only www.abnova.com Table of Contents Introduction... 3 Intended Use... 3 Background... 3 Principle of the Assay...
Female reproductive cycle: A Comprehensive Review Rachel Ledden Paper for Bachelors in Science January 20, 2018
Running head: 1 Female reproductive cycle: A Comprehensive Review Rachel Ledden Paper for Bachelors in Science January 20, 2018 Female reproductive cycle: A Comprehensive Review 2 The reproductive cycle
Factors influencing serum progesterone level on triggering day in stimulated in vitro fertilization cycles
ORIGINAL ARTICLE pissn 2233-8233 eissn 2233-8241 Clin Exp Reprod Med 2015;42(2):67-71 Factors influencing serum progesterone level on triggering day in stimulated in vitro fertilization cycles Ju Hee Park
First you must understand what is needed for becoming pregnant?
What is infertility? Infertility means difficulty in becoming pregnant without using contraception. First you must understand what is needed for becoming pregnant? Ovum from the woman to combine with a
Predictive factors for ovarian response in a corifollitropin alfa/gnrh antagonist protocol for controlled ovarian stimulation in IVF/ICSI cycles
Oehninger et al. Reproductive Biology and Endocrinology (2015) 13:117 DOI 10.1186/s12958-015-0113-1 RESEARCH Open Access Predictive factors for ovarian response in a corifollitropin alfa/gnrh antagonist
Reviews Induction of follicular growth and ovulation with urinary and recombinant gonadotrophins*
RBMOnline - Vol 3. No 1. 54 72 Reproductive BioMedicine Online webpaper 2001/050 on web 16 July 2001 Reviews Induction of follicular growth and ovulation with urinary and recombinant gonadotrophins* Dr